DR. HARRISON M. LAZARUS, MD

Plain English
This study examined the effects of starting treatment with all-trans retinoic acid (ATRA) quickly in patients diagnosed with acute promyelocytic leukemia (APL) in the emergency department. Researchers found that patients who received ATRA within the first 24 hours had a 10.2% chance of dying within 30 days, compared to 26.2% for those who started treatment later, indicating that early treatment reduced the risk of death by 16%. This is important because timely ATRA treatment can greatly improve survival rates and reduce serious complications like major bleeding. Who this helps: This benefits patients with acute promyelocytic leukemia and their healthcare providers.

Plain English
This study looked at how well a new inhaled form of pirfenidone works for patients with progressive pulmonary fibrosis, a severe type of lung disease. Researchers are testing the inhaled treatment on about 300 patients to see if it improves lung function after one year, alongside measuring quality of life and other health indicators. Previous oral forms of the drug haven’t shown significant benefits, so this inhaled version may offer a better option with fewer side effects. Who this helps: This helps patients with progressive pulmonary fibrosis.

Plain English
This study looked at how certain plant extracts can disrupt biofilms, which are clusters of microorganisms that make infections harder to treat and slow down wound healing. The researchers found that an extract was effective in preventing biofilm formation, reducing its growth by as much as 76% and inhibiting harmful substances produced by bacteria by 80% at a specific concentration. This is important because it could lead to new treatments that help fight infections more effectively, especially when antibiotics fail. Who this helps: This benefits patients with chronic infections and healthcare providers looking for better treatment options.

Plain English
This paper corrects a previous study about how plant leaf extracts can disrupt harmful biofilms, which are clusters of bacteria that can form on surfaces and cause infections. The research highlights that certain leaf extracts significantly reduce biofilm formation, which is important for preventing infections, particularly in medical settings. This matters because biofilms can make it harder to treat infections and lead to complications. Who this helps: This helps patients at risk of infections, especially those with medical devices or wounds.

Plain English
This study looked at how the blood type compatibility between donors and recipients affects the success of a specific cancer treatment called allogeneic hematopoietic cell transplantation (allo-HCT) for patients with acute leukemia. Researchers analyzed data from nearly 5,000 patients and found that those with a major mismatch in blood types between the donor and recipient had a 16% higher risk of dying after the transplant, had poorer recovery of their platelets, and were 60% more likely to experience primary graft failure compared to those with matching blood types. These findings highlight the importance of considering blood type compatibility when choosing donors for leukemia patients undergoing this treatment. Who this helps: Patients with acute leukemia who are considering allo-HCT.

Plain English
This study looked at how visceral obesity, which is fat stored around the belly, affects health outcomes and quality of life for patients with multiple myeloma who received a stem cell transplant. Researchers analyzed data from 549 patients and found that measures of visceral obesity, like waist-to-hip ratio, did not significantly impact how long patients lived without their cancer worsening or their overall survival. It also didn’t affect their quality of life after treatment, suggesting that visceral obesity may not be a key factor in their clinical outcomes. Who this helps: This helps patients with multiple myeloma and their doctors understand that visceral obesity may not have a major impact on treatment outcomes.

Plain English
This study looked at over 8,700 patients with acute myeloid leukemia (AML) to see how their risk classification at diagnosis affects their outcomes after a specific treatment called hematopoietic cell transplantation (HCT). Researchers found that patients with adverse-risk AML faced a 71% higher risk of relapse compared to those with intermediate-risk AML, and survival rates were significantly worse for those with KMT2A-rearranged or adverse-risk AML. These findings stress the importance of identifying a patient's risk at diagnosis, as it can guide treatment decisions and show that new therapies are needed for patients in higher-risk groups. Who this helps: This helps patients with acute myeloid leukemia and their doctors.

Plain English
This study examined how much NK (natural killer) cells can be safely given to patients after chemotherapy before causing problems. Researchers tested three different doses of NK cells on nine patients, with no one developing graft-versus-host disease (a common complication with donor cells) and no serious side effects causing them to stop the trial. The findings highlight that these NK cells can be safely administered and stay in the body for up to four weeks, suggesting they may be a promising treatment option for blood cancers and colorectal cancer. Who this helps: This helps patients with blood cancers and colorectal cancer who may benefit from new treatment options.

Plain English
This study looked at how mesenchymal stromal cells (MSCs) might help people with severe COVID-19, particularly those suffering from serious lung complications. Researchers found that MSCs could reduce inflammation and promote healing in the lungs of these patients. This is important because it offers a potential new treatment option for those facing severe respiratory issues due to COVID-19. Who this helps: This helps patients with severe COVID-19 and related respiratory problems.

Plain English
This study looked at how the health of the community impacts patients' survival after they receive a specific type of stem cell transplant called allogeneic hematopoietic cell transplantation (HCT). It included data from over 18,500 patients and found that those living in areas with poorer community health had worse survival rates; specifically, a higher community risk score (indicating a less healthy environment) was linked to a 4% increase in the risk of death from causes other than cancer. This matters because it highlights the importance of community health in patient outcomes, suggesting that improving community conditions could enhance survival rates for transplant patients. Who this helps: This helps patients and healthcare providers by emphasizing the need to consider community health when planning patient care.

Plain English
This study examined the effects of a low-dose treatment combining azacitidine, lenalidomide, and dexamethasone on patients with multiple myeloma who had not responded to previous therapies. Out of 51 patients screened, 42 received treatment, and 41 were measured for response. Overall, 22% showed a partial response, and the median survival time was 18.6 months, although the treatment had some side effects, notably low blood cell counts in 67% of the patients. Who this helps: This research benefits patients with relapsed or treatment-resistant multiple myeloma.

Plain English
This study examined how freezing donor stem cells affects the results of bone marrow transplants during the COVID-19 pandemic. Researchers found that patients receiving frozen stem cells from unrelated donors had slower recovery of immune cells and higher risks of complications and death. Specifically, frozen unrelated stem cell transplants led to 40% higher non-relapse mortality and 38% lower overall survival compared to fresh ones. Understanding these impacts is important for improving transplant outcomes and planning for future patient needs. Who this helps: This benefits patients undergoing bone marrow transplants and their doctors.

Plain English
Researchers studied whether a drug called tipifarnib could help prevent relapse in patients with acute myeloid leukemia (AML) who are in remission but at high risk of coming back. They found that those taking tipifarnib had a median time without relapse of 10.8 months compared to 5.3 months for those not receiving the drug, but this did not meet the threshold needed to consider the drug effective in general. This matters because finding effective maintenance treatments for high-risk AML patients could significantly improve their outlook; however, the study indicates tipifarnib is not the solution, as other better options might be available. Who this helps: This research benefits doctors and healthcare providers treating patients with AML, particularly those at high risk of relapse.

Plain English
This study looked at the effects of different pre-transplant treatments for adults aged 40 to 65 with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). It found that for patients with low to intermediate disease risk, a stronger treatment (myeloablative conditioning or MAC) led to better chances of staying cancer-free after a transplant, showing a 19% increased disease-free survival compared to a gentler treatment (reduced-intensity conditioning or RIC). However, for those with high disease risk, both treatments had similar outcomes. Who this helps: This research benefits patients with AML and MDS, especially those with low to intermediate disease risk.

Plain English
This study looked at how well older patients with acute myeloid leukemia (AML) survive after receiving stem cell transplants from different types of donors. Researchers found that five years after the transplant, about 32% of patients who received transplants from haploidentical donors (like siblings or children) were still alive, compared to 42% of those who received transplants from younger matched unrelated donors. This is important because it highlights that older patients may have better outcomes with matched unrelated donors, especially those under 40 years old. Who this helps: This helps patients with acute myeloid leukemia and their doctors in choosing the best transplant options.

Plain English
This study examined how to effectively treat and prevent sinusoidal obstruction syndrome (SOS), a serious condition that can occur after certain medical treatments like hematopoietic cell transplantation. Researchers found that while many patients with mild cases recover quickly, severe cases can lead to organ failure and have a mortality rate over 80%. Early detection and treatment are crucial, especially since a proven medication can significantly lower the risk of death. Who this helps: This benefits adult patients undergoing hematopoietic cell transplantation and their doctors.

Plain English
This study looked at whether taking tyrosine kinase inhibitors (TKIs) after receiving a stem cell transplant improves outcomes for adults with chronic myelogenous leukemia (CML). Researchers analyzed data from 390 patients and found that those who took TKIs after the transplant had a 5-year relapse rate of 35%, compared to 26% for those who didn’t take TKIs, but these differences were not significant. The findings suggest that maintaining TKI therapy after a transplant may not significantly affect overall survival or leukemia-free survival rates. Who this helps: This research benefits doctors treating patients with CML by providing insights into post-transplant treatment options.

Plain English
This study looked at bacterial bloodstream infections (BSIs) in patients who received hematopoietic cell transplants (alloHCT) within the first 100 days. Out of over 7,100 patients, 37% experienced at least one BSI, and those with BSIs had a significantly higher risk of death—1.82 times more likely for very early infections and 2.46 times more likely for infections later. This is important because it shows that BSIs are a serious risk for patients after transplantation and can affect their recovery and survival. Who this helps: This information benefits patients, doctors, and healthcare providers involved in post-transplant care.

Plain English
This study looked at how effective allogeneic hematopoietic cell transplantation (allo-HCT) is for patients with angioimmunoblastic T-cell lymphoma (AITL), especially those whose previous treatments failed. Researchers examined data from 249 AITL patients who underwent allo-HCT between 2000 and 2016. They found that 49% of patients were free of disease after four years, and 56% were still alive, showing that allo-HCT can be a strong option even for those who have not responded well in the past. Who this helps: This benefits AITL patients, particularly those who have experienced treatment failures.

Plain English
This study looked at infections from central nervous system viruses in patients who received hematopoietic stem cell transplants between 2007 and 2015. It found that 165 of over 27,000 patients tested positive for these viruses within six months of their transplant, especially human herpes virus 6, which was found in 73% of cases. The survival rates were concerning, with only 50% of patients surviving six months after the virus was detected and 30% surviving five years, making serious infections a major cause of death. Who this helps: This information benefits doctors treating transplant patients by highlighting the risks of viral infections and the need for close monitoring.

Plain English
This research looked at the results of a specific treatment called autologous hematopoietic cell transplantation (autoHCT) for men with germ cell tumors, a type of cancer. They found that survival rates improved significantly over 25 years; for example, the chance of being free from cancer three years after treatment jumped from 24% in the early 1990s to 47% by 2015. This improvement is linked to more patients receiving tandem transplants, which are done in pairs rather than one at a time, and to performing the transplant earlier in the treatment process. Who this helps: This benefits men with germ cell tumors and their doctors by providing better treatment options and improved survival rates.

Plain English
This study looked at how social and geographic factors affect access to a specific type of cancer treatment called allogeneic hematopoietic cell transplantation (alloHCT) for blood cancers like leukemia. It found that patients living in areas with higher poverty levels were less likely to receive this treatment; for every 10% increase in poverty, the likelihood of getting the transplant dropped by about 14%. This matters because it highlights unfair disparities in healthcare access that can be addressed to ensure all patients receive the necessary care. Who this helps: Patients from low-income communities suffering from blood cancers.

Plain English
This study looked at how to predict outcomes for patients with chronic lymphocytic leukemia (CLL) who have undergone a specific type of stem cell transplant. Researchers analyzed data from 606 patients and found that they could categorize patients into different risk levels: those at low risk had a 58% chance of not having their disease worsen after four years, while very high-risk patients only had a 25% chance. These findings matter because they help doctors better understand patient outcomes and make more informed decisions about treatment options. Who this helps: This helps patients with CLL, doctors, and researchers looking to improve treatment strategies.

Plain English
This study looked at the experiences of people donating stem cells for a second time and compared them to those donating for the first time. Researchers found that the feelings of pain and recovery times were similar for most donors when they donated again, but the amount of stem cells collected was lower with the second donation: for PBSC donations, the yield of important CD34 cells decreased. Understanding these experiences can help medical centers better prepare donors for repeat donations and make the process smoother and more effective. Who this helps: This helps both donors and healthcare providers involved in the stem cell donation process.

Plain English
This study looked at how well patients with multiple myeloma (MM) survive after their cancer returns, comparing two types of stem cell transplants: autologous/allogeneic (using both the patient's own cells and the donor's cells) and tandem autologous (using the patient’s own cells for both transplants). The results showed that 44% of patients who had the auto/allo transplant survived for at least six years after relapse, compared to 35% of those who had the auto/auto transplant. This is important because it suggests that the mixed transplant approach may lead to better long-term survival for patients whose MM comes back. Who this helps: Patients with multiple myeloma and their doctors.

Plain English
This study looked at whether a specific treatment called autologous hematopoietic cell transplant (autoHCT) can help patients with a type of blood cancer called follicular lymphoma (FL) who do not respond well to their first treatment. Out of the patients analyzed, those who received autoHCT within a year of treatment failure had a 5-year survival rate of 73%, compared to 60% for those who did not receive the transplant. This is important because it shows that early use of autoHCT can potentially lead to better survival for these patients. Who this helps: This helps patients with follicular lymphoma who experience early treatment failure.

Plain English
This study looked at the effects of early relapse in patients with multiple myeloma who underwent a specific type of treatment called autologous hematopoietic cell transplantation (AHCT). It found that 35-38% of patients relapsed within 24 months after the transplant, and those with early relapses had worse survival outcomes, particularly if they had factors like advanced cancer stage or certain types of the disease. However, the good news is that over the years, the overall outcomes for these patients have improved. Who this helps: This research helps patients with multiple myeloma and their doctors understand the risks of early relapse and the importance of ongoing treatment after transplantation.

Plain English
This study looked at the risk of developing acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in patients who underwent autotransplants for certain blood cancers between 1995 and 2010. Out of nearly 9,000 patients studied, 335 (3.7%) were diagnosed with either AML or MDS after their transplant. The research found that patients who received total body radiation as part of their treatment had a much higher risk of these conditions, with risks of AML being 10-50 times greater after autotransplantation. Who this helps: This helps patients who have undergone autotransplantation for Hodgkin lymphoma, non-Hodgkin lymphoma, or plasma cell myeloma.

Plain English
This study looked at different staging systems for newly diagnosed multiple myeloma patients who are about to undergo a specific type of transplant. The researchers found that the Revised International Staging System (R-ISS) did the best job of predicting patient survival compared to two other systems, showing that 88% of patients in the best category survived three years, while only 56% in the worst category did. This matters because using the R-ISS can help doctors better understand a patient's prognosis and tailor treatment plans accordingly. Who this helps: This helps patients with multiple myeloma and their doctors.

Plain English
This study looked at 693 patients with multiple myeloma who underwent autologous stem cell transplants after receiving different initial treatments. It found that the type of initial treatment (either a double or triplet therapy) did not significantly affect survival rates after the transplant, but those who received maintenance therapy afterward had a better chance of staying cancer-free for 3 years (55% versus 39%). This is important because it highlights that continuing treatment after the transplant can greatly improve outcomes, especially for patients who didn't fully respond to the initial therapy. Who this helps: This helps patients with multiple myeloma and their doctors in making informed treatment decisions.

Plain English
This study looked at the long-term effects of high-dose chemotherapy and stem cell transplants on patients with inflammatory breast cancer (IBC) compared to those with non-inflammatory breast cancer. Researchers found that the survival rates were similar for both groups, with a median survival of 40 months and a 10-year overall survival rate of 31% for IBC patients and 28% for non-IBC patients. However, those with stage III IBC had significantly worse outcomes and a higher risk of disease progression compared to those with stage III non-IBC. Who this helps: This information helps doctors and researchers understand the challenges faced by patients with IBC, guiding future treatment strategies.

Plain English
This study looked at the use and outcomes of a type of stem cell transplant called allogeneic hematopoietic cell transplantation (HCT) in patients aged 70 and older with blood cancers in the U.S. Between 2000 and 2013, the number of these transplants increased significantly, going from just 0.1% of all transplants in 2000 to 3.85% (298 transplants) in 2013. The survival rates also improved, with two-year overall survival rising from 26% to 39% and progression-free survival going from 22% to 32% during the same period, showing that older patients can benefit more from this treatment. Who this helps: This helps older patients with blood cancers by providing more treatment options and improving their chances of survival.

Plain English
This study looked at the safety and effectiveness of a treatment called autologous hematopoietic cell transplantation (AHCT) for multiple myeloma patients who have kidney problems. Among nearly 1,500 patients, those with severe kidney issues had a 5-year survival rate of 60%, and most patients on dialysis became independent of it after the procedure. This is important because it shows that AHCT can help multiple myeloma patients with kidney complications live longer and improve their quality of life. Who this helps: This helps multiple myeloma patients with kidney issues.

Plain English
This study looked at how early blood cell transplants for children with sickle cell disease in the U.S. affect survival rates and healthcare costs, comparing those who had transplants before age 10 to those who had later procedures. Researchers found that 90% of the 161 patients survived for at least two years, and late transplants were linked to significantly higher mortality (over 21 times worse) and more complications than early transplants. The average cost for a transplant was about $467,747, but early transplants were associated with lower hospital admissions and reduced costs after the procedure. Who this helps: This research benefits young patients with sickle cell disease and their families by providing insights for better treatment timing.

Plain English
This study looks at using umbilical cord blood for transplants in patients with acute myeloid leukemia (AML), especially when they don’t have compatible donors. It found that these transplants can cure about 30-40% of adults and 60-70% of children with AML. This matters because it provides a vital treatment option for patients who would otherwise have limited choices. Who this helps: Patients with acute myeloid leukemia.

Plain English
This study looked at the outcomes of patients with multiple myeloma who are considered high-risk compared to those who aren't, specifically after undergoing a certain type of stem cell transplant between 2008 and 2012. Researchers found that while both groups had similar immediate responses to treatment (about 59% for high-risk and 61% for non-high-risk patients at 100 days post-transplant), the three-year survival rates were significantly lower for high-risk patients, with only 37% remaining free of disease progression compared to 49% for non-high-risk patients. Additionally, high-risk patients who received post-transplant therapy had better outcomes, with 81% surviving three years, showing that additional treatment can help improve their prognosis. Who this helps: This information benefits patients with multiple myeloma, particularly those classified as high-risk, and their doctors by guiding treatment decisions.

Plain English
This study focused on understanding a specific protein from the Middle East respiratory syndrome coronavirus (MERS-CoV) called helicase, which is crucial for the virus to replicate. Researchers successfully produced and characterized this protein, discovering that it unwinds RNA and DNA while working best with longer strands of RNA. These findings are important because they offer a deeper understanding of how MERS-CoV operates, which could lead to new treatments that inhibit the virus's ability to reproduce. Who this helps: This benefits patients with MERS and healthcare professionals working to develop better treatments.

Plain English
This study looked at how metabolic syndrome, which includes obesity and diabetes, is connected to blood cancers. Researchers found that factors related to obesity and insulin resistance can trigger pathways in the body that make these cancers more aggressive and resistant to treatment. Understanding this connection is important because it opens up new treatment options, such as specific drugs that target these pathways, which could help improve outcomes for patients with these cancers. Who this helps: Patients with blood cancers related to metabolic syndrome.

Plain English
This study focused on how hematopoietic stem cell transplantation (HCT) can be used to treat multiple myeloma, a type of blood cancer. The researchers reviewed recent clinical trials and made recommendations based on solid evidence about when HCT should be used, including details on different types of HCT and necessary follow-up treatments. Their findings emphasize that HCT remains an important treatment option and that ongoing research continues to shape how it is applied. Who this helps: This helps patients with multiple myeloma and their doctors in making informed treatment decisions.

Plain English
This study examined the heart rhythm problems, known as arrhythmias, in patients aged 40 and older who received hematopoietic cell transplants for conditions like leukemia and lymphoma. Out of 1,177 patients, 104 experienced significant arrhythmias, with many developing these issues after the transplant. Those who had arrhythmias after the procedure faced longer hospital stays (32 days compared to 23 days for those without arrhythmias), were more likely to require intensive care (52% versus 7%), and had higher chances of dying in the hospital (28% versus 3%) and within a year (41% versus 15%). Who this helps: This research helps patients undergoing hematopoietic cell transplants, as well as their doctors, by highlighting the risks associated with post-transplant heart issues.

Plain English
This study looked at the impact of adding imatinib, a targeted drug, to the standard treatment for adults with a specific type of leukemia called Philadelphia positive acute lymphoblastic leukemia (ALL). It found that using imatinib increased the complete remission rate to 92% compared to 82% without it, and improved overall survival after four years from 22% to 38%. This is important because it shows that imatinib not only helps patients achieve remission but also increases their chances of living longer. Who this helps: This benefits patients with Philadelphia positive ALL and their doctors by providing a more effective treatment option.

Plain English
This study looked at how U.S. doctors who perform hematopoietic cell transplants (a type of treatment for blood cancers) approach the topic of preserving fertility for their patients. Out of 1,035 doctors invited to respond, 185 completed a survey. While most of them understood fertility preservation and felt comfortable talking about it, only 55% actually referred patients to specialists, and many didn’t provide helpful materials on the subject. Reasons included believing patients were too sick to delay treatment or thinking patients were already infertile due to previous therapies. Who this helps: This helps patients undergoing hematopoietic cell transplants and their families by highlighting the need for better support and resources regarding fertility preservation.

Plain English
This study looked at over 20,000 patients with multiple myeloma who had a specific type of stem cell transplant (called autologous transplantation) within a year of their diagnosis, comparing data from three different time periods (1995-1999, 2000-2004, and 2005-2010). It found that as time went on, more patients received this treatment, with survival rates improving from 47% to 57% over 15 years. This improvement is linked to better outcomes for patients who received the newest drug therapies alongside the transplant. Who this helps: Patients with multiple myeloma can benefit from this combination of treatments for better survival chances.

Plain English
This study tested a new drug called bardoxolone methyl in patients with advanced cancers and lymphomas to find the right dose, check for side effects, and see if it could shrink tumors. Researchers found that the maximum safe dose was 900 mg per day and that one patient with mantle cell lymphoma had a complete tumor response while another with anaplastic thyroid carcinoma had a partial response. The drug also improved kidney function, suggesting it may help patients with chronic kidney disease as well as cancer. Who this helps: This helps cancer patients, especially those with lymphoma and thyroid carcinoma, as well as patients with chronic kidney disease.

Plain English
This study looked at adult patients with a type of leukemia called B-acute lymphoblastic leukemia (B-ALL) to find important genetic changes and potential treatment targets. Researchers analyzed data from 215 patients and found that high levels of a protein called CD25 were linked to worse outcomes, suggesting it could be used as a new way to predict patient risk. They also discovered that targeting another protein, BCL6, could help treat a specific aggressive form of the disease caused by MLL gene changes. Who this helps: Patients with B-ALL, particularly those with the BCR-ABL1 and MLL rearrangements.